Article Details

Ikena Oncology maintains Buy stock rating despite discontinuing lead asset - Investing.com

Retrieved on: 2024-05-29 21:07:37

Tags for this article:

Click the tags to see associated articles and topics

Ikena Oncology maintains Buy stock rating despite discontinuing lead asset - Investing.com. View article details on hiswai:

Excerpt

On Wednesday, Ikena Oncology (NASDAQ:IKNA) received a reiterated Buy stock rating from TD Cowen, even after announcing the discontinuation of its ...

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up